Memidis Pharma enters partnership with Vésale Pharma of Belgium

The two firms have agreed that Memidis Pharma will market and distribute the Bacilac Femina product for the Netherlands only.

Recently there has been a lot of media attention following a Dutch study with Bacilac Femina in recurrent urinary tract infections in (post) menopausal women. This showed that prophylaxis with Bacilac Femina is almost as effective as antibiotics but has the great advantage that it does not develop resistance. Memidis Pharma therefore has high expectations of the market share that Bacilac Femina can gain.